Nigel Rudd
Partner @ Juno Capital Partners
London, United Kingdom
Nigel Rudd is a seed investor at Juno Capital Partners in London focused on Health Care and Dental. Sir Nigel Rudd is best known as founder of Williams plc in 1982, which went on to become one of the largest industrial holding companies in the United Kingdom until its demerger in November 2000, creating Chubb plc and Kidde plc. He is presently Chairman of BAA Limited and the technology company Invensys plc, and has been a long-term advocate of afund of this kind. Sir Nigel became Chairman of BGF in February 2011. Sir Nigel was knighted in 1996 for services to manufacturing. He has a long record as an active angel investor in small and medium-sized businesses. He has been Chairman of some of the largest companies in the UK, including Pilkington, Alliance Boots and the UK’s largest car retailer, Pendragon PLC, the company he founded with one dealership in 1982. He was a Director of Barclays PLC for 13 years, latterly as Deputy Chairman.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Nigel Rudd invests in
Stages Nigel Rudd invests in
Countries Nigel Rudd invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $15M–$15M
Investment Focus
Industry
- Health Care 2 (40%)
- Dental 1 (20%)
- Medical 1 (20%)
- Neuroscience 1 (20%)
- Biotechnology 1 (20%)
Stage
- Seed 1 (20%)
- Series A 1 (20%)
- Series B 1 (20%)
- Venture - Series Unknown 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Floe provides painless monitoring of your oral and systemic health and an innovative system for effective management | $489.5K / Seed / Oct 19, 2021 | ||
| Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. | $13.5M / Series B / Sep 01, 2017 | ||
| Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. | $15M / Series A / Feb 01, 2015 | ||
| Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. | $13M / Venture - Series Unknown / Feb 01, 2014 | ||
| See all 5 investments → | |||
Co-Investors
About Juno Capital Partners
Juno Capital is an innovative specialist alternative asset manager to a network of wealthy individuals and family offices – the “Syndicate Members”. Established in 2011, we target asset classes overlooked by mainstream asset managers and private banks, including venture capital, asset backed fixed income and niche property.Juno Capital wasfounded by Julian Hickman and Edward Rudd in 2011.
Juno Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Edward Rudd
Partner
|
|||
Claire Corbin
Partner & Operations Manager, Venture Investment
|
|||
Julian Hickman
Partner
|
|||
Malcolm Le May
Partner
|
|||
|
Nigel Rudd
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nigel Rudd invest in?
Nigel Rudd invests primarily in Health Care, Dental and Medical startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Nigel Rudd's check size?
Nigel Rudd typically joins rounds of $15M–$15M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Nigel Rudd participates in.
How do I contact Nigel Rudd?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Nigel Rudd last invest?
The most recent investment recorded for Nigel Rudd closed in Oct 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
